![Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals](https://www.frontiersin.org/files/Articles/573179/fimmu-11-573179-HTML-r1/image_m/fimmu-11-573179-g001.jpg)
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
Can Supply Chain Startups Provide a Digital Prescription for the Red Hot Personalized Autologous CAR-T Industry?
![Frontiers | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital Frontiers | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital](https://www.frontiersin.org/files/Articles/913287/fmed-09-913287-HTML-r1/image_m/fmed-09-913287-g001.jpg)
Frontiers | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
![BioInsights - Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain BioInsights - Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain](https://cdn.insights.bio/uploads/Thumbnails/450/SinclairFI.png)